FDA halts Avandia
July 22, 2010
FOLLOWING its decision to keep
the controversial diabetes pill,
Avandia, on the US market (PD 15
Jul), the Food and Drug Authority
has called a halt to a current
comparative study of the safety of
Avandia and its competitor, Actos.
The trial’s halt comes in response
to evidence presented to the FDA
when it was considering Avandia’s
position, that suggested the drug
heightened patients’ risk of heart
problems.
Although the evidence was not
definitive enough to keep the drug
off the market, it was enough for
the FDA to advise new patients
against enrolling in Avandia trials,
as well as forcing the halt to its
Actos study, which pitted both
drugs against each other in a bid to
see which one had the greater
safety profile.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jul 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jul 10